Tags: skin | disease | plaque | psoriasis

Idera Says Drug Safe, Well Tolerated in Skin Disease Study

Friday, 28 Mar 2014 07:41 AM

Idera Pharmaceuticals Inc. said its experimental drug for an inflammatory skin disease was found safe and well tolerated by patients after 12 weeks of treatment in a mid-stage trial.

The company's shares rose about 40 percent to $5.40 in premarket trading on Friday.

Idera said there were no treatment-related discontinuations or severe adverse events reported in the 32 patients with moderate-to-severe plaque psoriasis enrolled in the study.

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
Companies
Idera Pharmaceuticals Inc. said its experimental drug for an inflammatory skin disease was found safe and well tolerated by patients after 12 weeks of treatment in a mid-stage trial.
skin,disease,plaque,psoriasis
67
2014-41-28
Friday, 28 Mar 2014 07:41 AM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved